✦ LIBER ✦

Complete remission in patients with unresectable pancreatic cancer: dream or achievable event

✍ Scribed by Renata Dobrila-DintinjanaUH; Veridijana SunjicUH; Marijan DintinjanaPO; Drazen KovacUH

Book ID: 119391116
Publisher: Nature Publishing Group
Year: 2001
Tongue: English
Weight: 24 KB
Volume: 96
Category: Article
ISSN: 0002-9270
DOI: 10.1016/s0002-9270(01)03005-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Docetaxel is active in patients with unr

Docetaxel is active in patients with unresectable metastatic or locally advanced pancreatic cancer,

📂 Article 📅 2000 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

Palliation of biliary and duodenal obstr

Palliation of biliary and duodenal obstruction in patients with unresectable pancreatic cancer: Endoscopy or surgery?

✍ Maire, F.; Sauvanet, A. 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 953 KB

Mo1418 Analysis of the Incidence and Cli

Mo1418 Analysis of the Incidence and Clinical Characteristics of Thromboembolic Events in Patients With Unresectable Pancreatic Cancer

✍ Sugimoto, Hiroyuki; Hirooka, Yoshiki; Itoh, Akihiro; Kawashima, Hiroki; Ohno, Ei 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 111 KB

6589 Biweekly treatment with Docetaxel-G

6589 Biweekly treatment with Docetaxel-Gemcitabine and Erlotinib in patients with metastatic and/or unresectable pancreatic cancer offers a survival benefit

✍ Samelis, G.; Tsiakou, A.; Karamanides, M.; Pelechrini, M.; Zaganides, A.; Ekmekt 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

A phase II evaluation of goserelin and b

A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission

✍ Douglas Levine; Kay Park; Margrit Juretzka; Julie Esch; Martee Hensley; Carol Ag 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 263 KB

## Abstract ## BACKGROUND. The current study was conducted to determine the effect of goserelin and bicalutamide on progression‐free survival (PFS) in patients with epithelial ovarian cancer who were in second or greater complete disease remission. ## METHODS. Patients received bicalutamide at a

A phase 2 study of oral MKC-1, an inhibi

A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer

✍ Jason E. Faris, Jamie Arnott, Hui Zheng, David P. Ryan, Thomas A. Abrams, Lawren 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 169 KB